Driven to improve lives. #DiscoverDicerna
Location: United States, Massachusetts, Lexington
Employees: 201-500
Phone: 6176218097
Total raised: $159M
Founded date: 2007
Investors 8
Funding Rounds 4
| Date | Series | Amount | Investors |
| 30.03.2017 | - | $70M | - |
| 01.08.2013 | Series C | $60M | - |
| 21.10.2010 | Series B | $4M | - |
| 11.08.2010 | Series B | $25M | - |
Mentions in press and media 12
| Date | Title | Description |
| 04.03.2024 | Beta Catenin Market Key Players, Demand and Growth Trends by 2024-2031 | Boston Biomedical Inc, Marina Biotech Inc | Beta Catenin Market growth BURLINGAME, CALIFORNIA, UNITED STATES, March 4, 2024 /EINPresswire.com/ -- Beta Catenin Market Research focuses on the key trends prevailing in the Global Beta Catenin Industry sector. The existing Industry scenar... |
| 30.03.2017 | Dicerna Scores $70M | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that it has signed a stock purchase agreement with a s... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 18.10.2013 | Health IT deals help push software deals to 12-year high but life science struggles | Here were the biggest health IT deals for the quarter based on data from the MoneyTree Report and Mercom Capital Group’s Healthcare IT report. Evolent Health raised $100 million. EHR provider Practice Fusion raised $70 million. MedSynergies... |
| 01.08.2013 | Dicerna grabs $60M round to test RNAi tech on prime cancer suspect | Dicerna Pharmaceuticals has topped up its financial reserves with a $60 million C round earmarked to gather proof-of-concept data on a pair of RNAi programs headed for the clinic. And alongside the traditional venture investors who came bac... |
| 01.08.2013 | Dicerna Pharmaceuticals Inks $60M Series C | WATERTOWN, MA, Emerging pharmaceutical company developing RNA interference (RNAi)-based therapeutics, announced that it has closed $60 million in an oversubscribed Series C round of financing. >> Click here for more funding data on... |
| 01.08.2013 | Dicerna Secures $60 Million in Oversubscribed Series C Financing | |
| 01.08.2013 | Dicerna Pharmaceuticals Raises $60M in Series C Financing | Dicerna Pharmaceuticals, Inc., a Watertown, Mass.-based biopharmaceutical company developing RNA interference (RNAi)-based therapeutics against genetically-defined targets in multiple disease areas, raised $60m in Series C financing. The ro... |
| 21.10.2010 | Dicerna Pharmaceuticals Secures Additional $4M in Series B Financing | Dicerna Pharmaceuticals, Inc., a Watertown MA-based second generation RNA interference (RNAi) company developing novel therapeutics, secured an additional $4m in the second closing of its Series B equity financing. This brings the total cap... |
| 11.08.2010 | Dicerna Pharmaceuticals Closes $25M Series B Round of Financing | Dicerna Pharmaceuticals, Inc., a Watertown, Massachusetts-based RNAi-focused biopharmaceutical company developing novel therapeutic agents and related drug delivery systems in multiple disease areas utilizing its proprietary Dicer Substrate... |
Show more